Stem Cell Theranostics is a precision medicine-focused biotechnology company developing genetically-targeted therapies for heart failure.
The Impact of Heart Failure
Heart failure is a serious and growing medical concern. The global economic burden of heart failure is a staggering $110B. Genetic heart failure affects 1 in 500 people and touches the lives of nearly everyone. Still there are no approved drugs that treat the underlying causes of genetic heart disease. Additionally, drug-induced heart failure – which has a genetic basis – is responsible for 28% of drug withdrawals.
There is a critical need for translational preclinical models that address specific pathophysiology based on a patient’s genetic profile. Through our exclusive relationship with the Stanford Cardiovascular Institute, we have built a discovery platform that can be used to develop genetically-targeted therapies and simultaneously assess cardiotoxicity.